Guillain-Barre Syndrome Market Outlook 2031: From US$ 591.3 Million in 2022 to US$ 890.2 Million by 2031, Driven by Rising Incidence and Therapeutic Advancements

The global Guillain-Barre Syndrome (GBS) Market, valued at US$ 591.3 million in 2022, is projected to grow at a compound annual growth rate (CAGR) of 4.7% from 2023 to 2031, reaching US$ 890.2 million by 2031. GBS is a rare autoimmune neurological disorder where the immune system attacks peripheral nerves, causing muscle weakness and, in severe cases, paralysis. The market, encompassing treatments like intravenous immunoglobulin (IVIG) and plasma exchange, is driven by increasing GBS incidence, advancements in immunomodulatory therapies, and growing awareness. Challenges such as high treatment costs, limited awareness in developing regions, and regulatory complexities persist. This report provides a comprehensive analysis of the market, covering its overview, key drivers, challenges, regional insights, and future opportunities.

Get Sample PDF Brochure from here: https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=26765

Market Overview

The GBS Market includes therapeutics (IVIG, plasma exchange, others), diagnostics (lumbar puncture, nerve conduction studies), and supportive care for managing GBS symptoms. Valued at US$ 591.3 million in 2022, it is expected to reach US$ 890.2 million by 2031, driven by a CAGR of 4.7%. The market is segmented by therapeutics (IVIG, plasma exchange, others), route of administration (intravenous, subcutaneous), distribution channel (hospital pharmacies, retail pharmacies, online), disease variant (AIDP, AMAN, MFS, others), and region (North America, Europe, Asia-Pacific, Latin America, Middle East & Africa). IVIG dominates with a 52.35% share in 2024 due to its efficacy, while hospital pharmacies lead distribution.

Key Drivers of Growth

Several factors are propelling the growth of the GBS Market:

Rising Incidence of GBS: Annual global cases of 100,000, with 3,000-6,000 in the U.S., are linked to infections like COVID-19 (67% of cases follow respiratory/gastrointestinal infections), driving demand for treatments.

Advancements in Therapies: IVIG and plasma exchange, with innovations like subcutaneous immunoglobulin (7.78% CAGR), improve outcomes, boosting market adoption.

Aging Population: The elderly (projected 1.4 billion by 2030) are more susceptible to GBS, increasing treatment demand, especially in the 41-59 age group (USD 230.6 million in 2023).

Regulatory Support: Orphan drug designations, like Annexon's ANX005 in 2023, and FDA fast-track approvals accelerate therapy development.

Growing Awareness: Increased recognition of GBS as a rare disease, driven by studies like the University of Minnesota's 2023 findings, fuels diagnostic and therapeutic demand.

Top Companies:

Grifols S.A
CSL Behring LLC
Shire plc
Octapharma AG
Nihon Pharmaceutical Co., Ltd
Akari Therapeutics, PLC
China Biological Products Holdings, Inc.
Biotest AG
Kedrion S.p.A.

Visit our report to discover essential insights and analysis - https://www.transparencymarketresearch.com/guillain-barre-syndrome-market.html

Challenges and Barriers

Despite its growth potential, the market faces several challenges:

High Treatment Costs: IVIG treatments cost $10,000-$20,000 per course, limiting accessibility in low-income regions.

Limited Awareness in Developing Regions: Low knowledge among healthcare providers in Africa and parts of Asia-Pacific delays diagnosis and treatment.

Regulatory Complexities: Stringent requirements for approving biologics like complement inhibitors increase costs and delay market entry.

Safety Concerns: Risks like thromboembolism with high-dose IVIG may shift preference to safer biologics, impacting market dynamics.

Inconsistent Market Estimates: Varying projections (e.g., USD 1.01 billion by 2030 at 5.77% CAGR or USD 960.58 million by 2032 at 5.1% CAGR) create uncertainty.

Regional Insights

The GBS Market exhibits distinct regional dynamics:

North America: Dominates with a 44.24% share in 2024 (USD 305.4 million in 2023), driven by advanced healthcare, high GBS incidence, and R&D. The U.S. leads with 69.75% of the regional market.

Europe: Significant share, with Germany, France, and the UK benefiting from high GBS incidence (1-2 per 100,000 annually) and supportive policies like the EU's Orphan Drug Regulation.

Asia-Pacific: Fastest-growing region, with a 5.1% CAGR, fueled by rising autoimmune disease cases, healthcare investments, and diagnostics growth in China, India, and Japan.

Latin America: Moderate growth, with Brazil leading due to improving healthcare infrastructure. Limited awareness slows adoption.

Middle East & Africa: Smallest share due to limited healthcare access. Growth opportunities exist in Gulf countries with rising investments.

Future Opportunities

The GBS Market offers several avenues for growth and innovation:

Complement Inhibitors: Therapies like tanruprubart, showing better disability scores than IVIG, could become first-line treatments by 2030.

Subcutaneous Therapies: Growing at a 7.78% CAGR, subcutaneous immunoglobulin offers patient-friendly home infusion options.

Expansion in Emerging Markets: Rising healthcare investments in Asia-Pacific and Latin America present opportunities for affordable therapies.

Advanced Diagnostics: Innovations in lumbar puncture and nerve conduction studies, with a diagnostics market reaching USD 196.7 million by 2034, enhance early detection.

Collaborations: Partnerships, like Grifols' with the European Neurological Society, can accelerate R&D and market reach.

Browse More Trending Research Reports:

Liquid Filled Hard Capsules Market: https://www.globenewswire.com/news-release/2023/7/4/2699010/0/en/Liquid-Filled-Hard-Capsules-Market-to-Grow-at-a-CAGR-of-7-8-from-2022-to-2031-reaching-US-4-0-billion-As-per-TMR-Study.html

Oral Rehydration Solution [ORS] Market: https://www.globenewswire.com/news-release/2023/10/05/2755222/32656/en/Oral-Rehydration-Solution-ORS-Market-to-Exceed-USD-6-71-billion-by-2031-Capturing-a-9-9-CAGR-TMR-Report.html

Atopic Dermatitis Drugs Market: https://www.globenewswire.com/news-release/2023/07/31/2715115/32656/en/Atopic-Dermatitis-Drugs-Market-to-Grow-at-a-CAGR-of-14-7-from-2022-to-2031-reaching-USD-29-4-Billion-As-per-TMR-Study.html

Oligonucleotides Market: https://www.globenewswire.com/news-release/2024/12/02/2989923/32656/en/Oligonucleotides-Market-Outlook-2034-Projected-to-Reach-US-13-1-Billion-by-2034-Driven-by-Expanding-Applications-in-Biotechnology-and-Precision-Medicine-TMR.html

About Transparency Market Research

Transparency Market Research, a global market research company registered at Wilmington, Delaware, United States, provides custom research and consulting services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insights for thousands of decision makers. Our experienced team of Analysts, Researchers, and Consultants use proprietary data sources and various tools & techniques to gather and analyses information.

Our data repository is continuously updated and revised by a team of research experts, so that it always reflects the latest trends and information. With a broad research and analysis capability, Transparency Market Research employs rigorous primary and secondary research techniques in developing distinctive data sets and research material for business reports.

Contact Us:

Transparency Market Research Inc.
CORPORATE HEADQUARTER DOWNTOWN,
1000 N. West Street,
Suite 1200, Wilmington, Delaware 19801 USA
Tel: +1-518-618-1030
USA - Canada Toll Free: 866-552-3453
Website: https://www.transparencymarketresearch.com

This release was published on openPR.